157 related articles for article (PubMed ID: 37855394)
1. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E
Sun G; Fuller H; Fenton H; Race AD; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
Int J Cancer; 2024 Mar; 154(5):873-885. PubMed ID: 37855394
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies JR; Mell T; Fuller H; Harland M; Saleh RNM; Race AD; Rees CJ; Brown LC; Loadman PM; Downing A; Minihane AM; Williams EA; Hull MA
Cancer Prev Res (Phila); 2023 Nov; 16(11):621-629. PubMed ID: 37756582
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
6. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.
Petrucci G; Giaretta A; Ranalli P; Cavalca V; Dragani A; Porro B; Hatem D; Habib A; Tremoli E; Patrono C; Rocca B
Clin Transl Sci; 2022 Dec; 15(12):2958-2970. PubMed ID: 36200184
[TBL] [Abstract][Full Text] [Related]
7. Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial.
Fuller H; Race AD; Fenton H; Burke L; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
Prostaglandins Leukot Essent Fatty Acids; 2023 May; 192():102570. PubMed ID: 37003144
[TBL] [Abstract][Full Text] [Related]
8. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
Downing A; Fenton H; Nickerson C; Loadman PM; Williams EA; Rees CJ; Brown LC; Morris EJA; Hull MA
Aliment Pharmacol Ther; 2023 Sep; 58(6):562-572. PubMed ID: 37518954
[TBL] [Abstract][Full Text] [Related]
9. Effects of nabumetone on prostanoid biosynthesis in humans.
Cipollone F; Ganci A; Panara MR; Greco A; Cuccurullo F; Patrono C; Patrignani P
Clin Pharmacol Ther; 1995 Sep; 58(3):335-41. PubMed ID: 7554708
[TBL] [Abstract][Full Text] [Related]
10. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
Cipollone F; Patrignani P; Greco A; Panara MR; Padovano R; Cuccurullo F; Patrono C; Rebuzzi AG; Liuzzo G; Quaranta G; Maseri A
Circulation; 1997 Aug; 96(4):1109-16. PubMed ID: 9286937
[TBL] [Abstract][Full Text] [Related]
11. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.
Santilli F; Paloscia L; Liani R; Di Nicola M; Di Marco M; Lattanzio S; La Barba S; Pascale S; Mascellanti M; Davì G
J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25037196
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
[TBL] [Abstract][Full Text] [Related]
13. Platelet activation in patients with colorectal cancer.
Sciulli MG; Filabozzi P; Tacconelli S; Padovano R; Ricciotti E; Capone ML; Grana M; Carnevale V; Patrignani P
Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):79-83. PubMed ID: 15626589
[TBL] [Abstract][Full Text] [Related]
14. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
15. Aspirin dosage and thromboxane synthesis in patients with vascular disease.
Hart RG; Leonard AD; Talbert RL; Pearce LA; Cornell E; Bovill E; Feinberg WM
Pharmacotherapy; 2003 May; 23(5):579-84. PubMed ID: 12741431
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method.
Mizugaki M; Hishinuma T; Matsumura E; Murai Y; Yamazaki T; Yamanobe S; Tamai M
Prostaglandins Other Lipid Mediat; 1999 Nov; 58(5-6):253-62. PubMed ID: 10593167
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man.
Chiabrando C; Rivoltella L; Alberti E; Bonollo M; Djurup R; Fanelli R
Prostaglandins; 1993 May; 45(5):401-11. PubMed ID: 8321910
[TBL] [Abstract][Full Text] [Related]
18. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Platelets; 2011; 22(3):188-95. PubMed ID: 21231857
[TBL] [Abstract][Full Text] [Related]
19. Significance of urinary 11-dehydro-thromboxane B
Simeone P; Boccatonda A; Liani R; Santilli F
Ageing Res Rev; 2018 Dec; 48():51-78. PubMed ID: 30273676
[TBL] [Abstract][Full Text] [Related]
20. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B
Gurbel PA; Bliden KP; Tantry US
J Thromb Thrombolysis; 2021 Feb; 51(2):260-264. PubMed ID: 33170486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
